These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30731371)

  • 1. Stroke prevention in atrial fibrillation: Closing the gap.
    Pokorney SD; Gersh BJ; Ahmad A; Al-Khatib SM; Blank M; Coylewright M; DiBattiste P; Healey JS; Hedrich O; Hylek EM; Kline-Rogers E; Peterson ED; Mendys P; Mirro MJ; Naccarelli G; Patel P; Ruff CT; Rutman H; Stockbridge N; Temple R; Granger CB
    Am Heart J; 2019 Apr; 210():29-38. PubMed ID: 30731371
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison between vitamin K antagonists and new oral anticoagulants.
    Jolobe OMP
    Br J Clin Pharmacol; 2017 Nov; 83(11):2589-2590. PubMed ID: 28703392
    [No Abstract]   [Full Text] [Related]  

  • 3. Which oral anticoagulant for atrial fibrillation.
    Med Lett Drugs Ther; 2016 Apr; 58(1492):45-6. PubMed ID: 27049507
    [No Abstract]   [Full Text] [Related]  

  • 4. Analysis of Recurrent Stroke Volume and Prognosis between Warfarin and Four Non-Vitamin K Antagonist Oral Anticoagulants' Administration for Secondary Prevention of Stroke.
    Kanai Y; Oguro H; Tahara N; Matsuda H; Takayoshi H; Mitaki S; Onoda K; Yamaguchi S
    J Stroke Cerebrovasc Dis; 2018 Feb; 27(2):338-345. PubMed ID: 29033229
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative efficacy and safety of non-Vitamin K oral anticoagulants for non-valvular atrial fibrillation: Network meta-analysis comparing apixaban, dabigatran, rivaroxaban and edoxaban in three patient subgroups.
    Lip GY; Mitchell SA; Liu X; Liu LZ; Phatak H; Kachroo S; Batson S
    Int J Cardiol; 2016 Feb; 204():88-94. PubMed ID: 26655548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Not Available].
    Oldgren J
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512140
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparing the Cost Effectiveness of Non-vitamin K Antagonist Oral Anticoagulants with Well-Managed Warfarin for Stroke Prevention in Atrial Fibrillation Patients at High Risk of Bleeding.
    Hospodar AR; Smith KJ; Zhang Y; Hernandez I
    Am J Cardiovasc Drugs; 2018 Aug; 18(4):317-325. PubMed ID: 29740750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonvitamin K-dependent oral anticoagulants (NOACs) in chronic kidney disease patients with atrial fibrillation.
    Di Lullo L; Ronco C; Cozzolino M; Russo D; Russo L; Di Iorio B; De Pascalis A; Barbera V; Galliani M; Vitaliano E; Campana C; Santoboni F; Bellasi A
    Thromb Res; 2017 Jul; 155():38-47. PubMed ID: 28482261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.
    Potpara TS; Lip GY
    JAMA; 2017 Mar; 317(11):1115-1116. PubMed ID: 28208176
    [No Abstract]   [Full Text] [Related]  

  • 10. Use of direct oral anticoagulants in patients with nonvalvular atrial fibrillation according to clinical profile.
    Barrios V; Masjuan J
    Future Cardiol; 2017 Jan; 13(1):49-64. PubMed ID: 27731650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Renal Function Considerations for Stroke Prevention in Atrial Fibrillation.
    Fanikos J; Burnett AE; Mahan CE; Dobesh PP
    Am J Med; 2017 Sep; 130(9):1015-1023. PubMed ID: 28502818
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ninety-day prognosis of patients receiving direct oral anticoagulants in the early phase of non valvular atrial fibrillation-related acute ischemic stroke: The real life evidence.
    Masotti L; Grifoni E; Dei A; Vannucchi V; Moroni F; Spolveri S; Panigada G; Landini G
    Thromb Res; 2018 Dec; 172():165-168. PubMed ID: 30419471
    [No Abstract]   [Full Text] [Related]  

  • 13. Methodological challenges in assessment of current use of warfarin among patients with atrial fibrillation using dispensation data from administrative health care databases.
    Sinyavskaya L; Matteau A; Johnson S; Durand M
    Pharmacoepidemiol Drug Saf; 2018 Sep; 27(9):979-986. PubMed ID: 29869382
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
    Martinez BK; Sood NA; Bunz TJ; Coleman CI
    J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
    Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
    BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety of NOACs in atrial fibrillation patient subgroups: A narrative review.
    Lip GYH
    Int J Clin Pract; 2019 Feb; 73(2):e13285. PubMed ID: 30334313
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sex-Specific Comparative Effectiveness of Oral Anticoagulants in Elderly Patients With Newly Diagnosed Atrial Fibrillation.
    Palamaner Subash Shantha G; Bhave PD; Girotra S; Hodgson-Zingman D; Mazur A; Giudici M; Chrischilles E; Vaughan Sarrazin MS
    Circ Cardiovasc Qual Outcomes; 2017 Apr; 10(4):. PubMed ID: 28408716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute management of stroke patients taking non-vitamin K antagonist oral anticoagulants Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry: Design and rationale.
    Xian Y; Hernandez AF; Harding T; Fonarow GC; Bhatt DL; Suter RE; Khan Y; Schwamm LH; Peterson ED
    Am Heart J; 2016 Dec; 182():28-35. PubMed ID: 27914497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
    Hernandez I; Zhang Y; Saba S
    Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [COMPARATIVE EFFECTIVENESS AND SAFETY OF NEW ORAL ANTICOAGULANTS AND WARFARIN IN PATIENTS WITH AGE-SPECIFIC NON-VALVULAR ATRIAL FIBRILLATION].
    Shevelev VI; Kanorsky SG
    Klin Med (Mosk); 2015; 93(7):30-6. PubMed ID: 26596056
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.